EPCAM and cancer: A proportion of EPCAM+ cancer cells (median, 21,286; range, 129–197,205) expressed HLA-DRA (Fig. 4e), with a median ratio of 10.28% (range, 1.08–79.6%; Fig. 4d and Supplementary Table 5).